India’s Pharma Exports Set to Surge 10x, Aiming for ₹30,76,500 Crore by 2047

India, long recognised as the pharmacy of the world, is set to experience a significant expansion in pharmaceutical exports. With a target of ₹30,76,500 crore (US$ 350 billion) by 2047, the country’s pharma industry is expected to grow 10 to 15 times from its current export value of ₹2,37,330 crore (US$ 27 billion) in 2023.

The roadmap for this growth involves shifting from a volume-based approach to a value-driven strategy, focusing on speciality generics, biosimilars, and high-value pharmaceutical innovations.

A Transition Towards High-Value Products

Historically, India has dominated the global generic drugs market, supplying over 20% of the world’s generic medicines. However, to reach the ambitious 2047 export target, the industry is gearing up for a strategic transformation. Key focus areas include:

• Expanding the Active Pharmaceutical Ingredients (API) segment
• Scaling up biosimilar exports
• Enhancing the role of specialty generics
• Investing in innovative formulations and advanced R&D

By 2030, India’s pharma exports are projected to reach ₹5,71,350 crore (US$ 65 billion) before further expanding to ₹30,76,500 crore (US$ 350 billion) by 2047.

API and Biosimilar Exports to Drive Growth

A recent news report highlights that API exports are expected to surge from ₹43,950 crore (US$ 5 billion) in 2023 to between ₹7,03,200 crore and ₹7,91,100 crore (US$ 80-90 billion) by 2047.

Similarly, biosimilar exports are anticipated to grow fivefold, reaching ₹2,63,700 – ₹3,07,650 crore (US$ 30-35 billion). The emphasis on biosimilars aligns with the global demand for cost-effective alternatives to biologic drugs.

Meanwhile, generic formulations, which currently make up the largest share of India’s pharma exports, are expected to scale up to ₹15,82,200 – ₹16,70,100 crore (US$ 180-190 billion) by 2047, with an increasing share of speciality generics that offer higher profit margins.

Strategic Investments and Policy Support

For India to sustain this exponential export growth, a combination of government support, industry collaboration, and private-sector investment will be required. Key enablers include:

1. Stronger policy frameworks – Ensuring regulatory compliance and streamlined approvals for new drug development.
2. Boosting R&D investments – Encouraging research in high-value segments like biologics and personalised medicine.
3. Strengthening CDMO and CRO partnerships – Enhancing India’s role in contract development and research to meet global demand.
4. Scaling production capacity – Expanding manufacturing infrastructure to cater to growing international markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.